MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo aims had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of the exploratory https://aneurinn010lzj5.rimmablog.com/profile